A Cost-Effectiveness Analysis of Amivantamab Plus Lazertinib Versus Osimertinib in the Treatment of US and Chinese Patients with EGFR-mutated Advanced Non-Small Cell Lung Cancer.
Lung cancer (Amsterdam, Netherlands)（2025）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要